Skip to main content
    P

    Processa Pharmaceuticals Inc (PCSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.73
    +0.01 (+0.58%)

    Market Cap: $4.81M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Processa Pharmaceuticals Inc (PCSA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Processa Pharmaceuticals (PCSA) has a market cap of $4.81M. It holds $180.21M more cash than debt, 3744.13% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Market Cap$4.81M
    Latest price (Nov 17, 2026)$1.73

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 8.12% in the quarter ended Sep 30, 2026.

    Shares Outstanding2.97M
    Shares Change (QoQ)+8.12%

    Price Statistics

    The stock is down 76.93% over 52 weeks and trades 3.35% below its 50-day average.

    Beta (1Y)1.15
    52-Week Change-76.93%
    3-Month Change-19.53%
    6-Month Change-33.72%
    5-Year Change-99.95%
    Total Return (1Y)-76.93%
    Total Return (3Y CAGR)-79.95%
    Total Return (5Y CAGR)-77.25%
    Return vs SPY (1Y)-88.94%
    Max Drawdown (1Y)-82.35%
    Max Drawdown (3Y)-99.68%
    Sharpe Ratio (1Y)-0.94
    Correlation with SPY (1Y)0.10
    50-Day Average$1.79
    200-Day Average$2.28
    52-Week Range$1.04 to $8.88
    RSI (14 Days)43.5
    Average Volume (20 Days)27.12K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 97.70x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio97.70x
    Quick Ratio97.70x
    Debt / Equity0.00x

    Scores

    PCSA has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$301
    Operating Income-$193.50M
    Pretax Income-$193.09M
    Net Income-$193.16M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$180.21M
    Total Debt$0
    Net Cash$180.21M
    Net Cash Per Share$60.59
    Working Capital$180.15M
    Shareholder Equity-$181.38M
    Total Assets$182.01M
    Total Liabilities$1.86M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$13.66M
    FCF Per Share-$4.88
    Depreciation and Amortization$1.30K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    PCSA does not pay a dividend.

    Buyback Yield-3706.01%
    Shareholder Yield-3706.01%

    Stock Splits

    The last split was a 1-for-25 reverse split on Dec 17, 2025.

    Last Split DateDec 17, 2025
    Split TypeReverse split
    Split Ratio1:25

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PCSA

    What is PCSA's market cap?

    Processa Pharmaceuticals has a market cap of $4.81M.

    How many shares of PCSA are outstanding?

    Processa Pharmaceuticals has 2.97M shares outstanding.

    Does PCSA pay a dividend?

    No. Processa Pharmaceuticals does not pay a dividend.

    How much debt does PCSA have?

    Processa Pharmaceuticals has $0 of total debt and $180.21M of cash and equivalents, a net cash position of $180.21M.